Vical (VICL) Misses Q3 EPS by 1c; Revenues Above Consensus
More News related to VICL
- Vical Completes Final Patient Follow-Up in TransVax(TM) CMV Vaccine Phase 2 Trial
- Vical Added to NASDAQ Biotechnology Index
- Semi-Annual Changes to the NASDAQ Biotechnology Index
- Vical's DNA Vaccine Technology Addresses Challenges of Emerging Diseases
- Vical (VICL) Misses Q3 EPS by 1c; Revenues Above Consensus
More News related to Earnings
- Wunderlich Securities Downgrades Gran Tierra Energy (GTE) to Hold
- Stephens Downgrades Benihana (BNHN) to Equalweight
- UBS Downgrades NRG Energy (NRG) to Neutral; Cuts Target to $26
- Citi Cuts Lukoil (LUKOY) to Hold
Vical Incorporated (Nasdaq: VICL) reports a Q3 loss of $0.14, 1 cent worse than estimates. Revenues were $3.9 million vs. $3.29 million consensus.
The company's third quarter 2009 net cash burn was consistent with the company's prior guidance of a full-year 2009 net cash burn of between $19 million and $23 million. Vical raised net proceeds of approximately $29 million through registered direct offerings during the first nine months of 2009, and had cash and investments of $55 million at September 30, 2009.
[SM]
Related Categories
EarningsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
